← Search & browse all drugs

bupranolol

C07AA19

Forms & Strengths

Oral tablets 1 mg
Oral tablets 5 mg
Solution for ophthalmic use 0.25%

Adult Dosing

Hypertension: 1 mg to 5 mg orally 2 to 3 times daily, adjusted based on clinical response
Angina pectoris: 1 mg to 5 mg orally 2 to 3 times daily
Glaucoma (ophthalmic): 1 drop into the affected eye(s) 1 to 2 times daily

Pediatric Dosing

Safety and efficacy in pediatric patients have not been established; use is generally not recommended

Indications

Hypertension
Angina pectoris
Chronic open-angle glaucoma (ophthalmic formulation)

Mechanism of Action

Non-selective beta-adrenergic receptor antagonist (beta-blocker) blocking both beta-1 and beta-2 adrenergic receptors
Decreases heart rate, myocardial contractility, and cardiac output
Lowers blood pressure by reducing sympathetic outflow from the CNS and renin release from the kidneys

Contraindications

Known hypersensitivity to bupranolol or other beta-blockers
Sinus bradycardia and second- or third-degree atrioventricular block
Cardiogenic shock and overt cardiac failure
Bronchial asthma or severe chronic obstructive pulmonary disease

Adverse Reactions

Bradycardia, hypotension, and exacerbation of heart failure
Fatigue, dizziness, sleep disturbances, and depression
Cold extremities, Raynaud's phenomenon, and paresthesias
Bronchospasm and dyspnea in susceptible patients
Gastrointestinal disturbances including nausea and diarrhea

Drug Interactions

Additive bradycardia and AV nodal conduction slowing with calcium channel blockers (e.g., verapamil, diltiazem) and digitalis glycosides
Enhanced hypotensive effect when co-administered with antihypertensive agents, diuretics, or vasodilators
Increased risk of severe rebound hypertension upon abrupt withdrawal of clonidine
Potentiation of hypoglycemia and masking of tachycardia symptoms in patients taking insulin or oral hypoglycemic agents

Curated Content: Needs Vetting Before Put to Clinical Use